This patent infringement case involves Glenmark Pharmaceuticals' efforts to bring a generic version of Zetia® to market in the United States. It seeks to do so by avoiding, or invalidating altogether, Schering-Plough's so-called ‘721 patent, a patent for the hydroxylsubstituted azetidinones compound ezetimibe, marketed and sold commercially as the cholesterol-management drug Zetia®.
I have previsouly set up the background on this case, and some of the other in-substance patent cliffs faced by Schering-Plough, here.
It now looks likely that this trial could begin, even before year-end:
. . . .Oral argument on the parties’ informal submissions regarding the Final Pretrial Order shall be heard on November 24, 2009 at 2:00 P.M. before the undersigned in Courtroom 2D of the Martin Luther King, Jr. Courthouse.SO ORDERED.
/s/ Esther Salas
Esther Salas, U.S.M.J. . . .
Stay-tuned, as Zetia made close to a billion in sales revenue last year, all by itself, for Schering-Plough.
No comments:
Post a Comment